Thomas Kintanar, MD
Family Medicine · Fort Wayne, INNPI 1750326351
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $123,511 of the $184,990 with a category attached, or 66.8%. It is spread thinly across 59 manufacturers, the largest accounting for just 23.9%. Among family medicine clinicians in IN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,556 payments — averaging $118.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Phathom Pharmaceuticals, Inc.$44K
- Astellas Pharma US Inc$42K
- Otsuka America Pharmaceutical, Inc.$35K
- Bayer$26K
- Sanofi-aventis U.S. LLC$18K
- Novo Nordisk$3K
- plus $17K from 53 others
What the payments were for
- Consulting fees$7,1764%
- Speaking & faculty fees$123,51167%
- Travel & lodging$27,40215%
- Food & beverage$26,57514%
- Education$3260%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$184,990 in reported general payments places this provider in the 95th percentile of 2,709 family medicine providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 677 | $275,229 |
| OzempicSemaglutide | 171 | $202,563 |
| JardianceEmpagliflozin | 141 | $146,485 |
| TrulicityDulaglutide | 118 | $129,361 |
| MounjaroTirzepatide | 111 | $122,745 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 95 | $80,819 |
| JanuviaSitagliptin Phosphate | 93 | $78,717 |
| KerendiaFinerenone | 42 | $63,665 |
| FarxigaDapagliflozin Propanediol | 53 | $62,080 |
| RybelsusSemaglutide | 20 | $54,883 |
| GemtesaVibegron | 139 | $49,831 |
| XareltoRivaroxaban | 84 | $43,113 |
| XifaxanRifaximin | 34 | $38,444 |
| RexultiBrexpiprazole | 17 | $36,344 |
| NuedextaDextromethorphan Hbr/Quinidine | 41 | $33,898 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis, Nurtec Odt | $1,846 | $294,505688 claims |
| Novo NordiskOzempic, Rybelsus | $3,398 | $257,446191 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $1,386 | $252,105229 claims |
| Boehringer IngelheimJardiance, Tradjenta, Stiolto Respimat, Combivent Respimat | $692 | $195,400227 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $774 | $98,442165 claims |
| MerckJanuvia | $599 | $78,71793 claims |
| BayerKerendia | $25,651 | $63,66542 claims |
| AstraZenecaFarxiga | $2,303 | $62,08053 claims |
| Johnson & JohnsonXarelto, Invokana | $558 | $58,195101 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $277 | $49,831139 claims |
| AbbVieLinzess, Creon | $3,058 | $40,67553 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan | $516 | $38,44434 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,709 family medicine providers in Indiana.
Other family medicine in Fort Wayne
- Brianna SerbusFort Wayne$174K
- Brian AdamsFort Wayne$173K
- Charles CoatsFort Wayne$38K
- Beulah PenumudiFort Wayne$38K
- Nehal SinghFort Wayne$20K
- Peter JakackiFort Wayne$19K
- Sarah TurnerFort Wayne$17K
- Hector PerezFort Wayne$16K
- Richard TannerIndianapolis$1.6M
- James AndryBloomington$715K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.